Dr. Feng Ren, Chief Scientific Officer (CSO) and head of global research and development is named co-CEO of Insilico Medicine Highlights: Insilico Medicine is a global, end-to-end, fully-integrated AI-powered biotechnology company with three business models: AI platform, collaboration, and internal pipeline. It utilizes AI and a fully distributed, highly parallel discovery model to rapidly develop its own drugs. Since 2021, the company has nominated 8 preclinical candidates and reached Phase I clinical trials with an AI-discovered and AI-designed molecule. It is also developing a set of AI platforms for target discovery, multi-parameter optimization, generative chemistry, and prediction of clinical trials. In the pharmaceutical industry, the internal pipeline, and especially, clinical assets, are much more important and expensive than computational platforms and other enabling technologies. Historically, companies in computationally-augmented discovery, reduced or completely eliminated